Stifel raises Leidos stock price target to $204 on strong Q2 results

Leidos Holdings (NYSE:LDOS) reported robust Q2 2025 financial results, with EPS of $3.21, exceeding forecasts by 21.59%, and revenue of $4.25 billion, prompting Stifel to raise its price target to $204 from $178 while maintaining a Buy rating. The defense and technology company, which also surpassed EBITDA estimates by 18%, raised its fiscal year 2025 guidance, citing exceptional margins and medium-term growth opportunities, despite its stock already surging over 20% year-to-date and being in overbought territory.

Analysis

Leidos Holdings (LDOS) delivered a robust second-quarter 2025 performance, significantly surpassing analyst expectations and prompting a positive revision to its outlook. The defense and technology firm reported an earnings per share of $3.21, a 21.59% beat over the forecasted $2.64, and an 18% beat on EBITDA estimates. This strong bottom-line result, supported by revenue of $4.25 billion, was driven by exceptional margins, particularly within its Healthcare segment, indicating a recovery from first-quarter challenges. In response to this operational strength, Leidos raised its full-year 2025 guidance. The results also catalyzed a price target increase from Stifel to $204.00 from $178.00, with the firm maintaining a Buy rating and citing medium-term growth catalysts such as the Golden Dome, Border Security, and FAA modernization projects. This fundamental strength, rated as "GREAT" by InvestingPro, is set against a backdrop of significant stock appreciation, with a year-to-date surge of over 20% that has pushed the stock into what technical indicators suggest is overbought territory.

Key Decisions for Investors

• Given the significant earnings beat, raised FY25 guidance, and strong analyst conviction, investors may consider the fundamental picture supportive of a long position, particularly if focused on medium-term growth catalysts.
• However, with the stock up over 20% year-to-date and technical indicators signaling an overbought condition, new investors should be cautious of a potential near-term price consolidation or pullback before initiating a position.
• Existing holders should closely monitor margin performance in subsequent quarters to ensure the Healthcare segment's strength is sustainable, and track execution on key projects like FAA modernization and Border Security which are critical to realizing the updated price target.